A prospective study comparing rivaroxaban to the low-molecular-weight heparin (LMWH) dalteparin, the current standard of care, for the treatment of blood clots in patients with active cancer

Trial Profile

A prospective study comparing rivaroxaban to the low-molecular-weight heparin (LMWH) dalteparin, the current standard of care, for the treatment of blood clots in patients with active cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Cancer; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms CALLISTO
  • Most Recent Events

    • 02 Jun 2015 New trial record
    • 28 May 2015 This study is a part of CALLISTO clinical research program. This program consists of seven clinical studies and two observational registries.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top